查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1613213

危急性肢体缺血治疗市场：依治疗类型、最终用户划分 - 全球预测 2025-2030

Critical Limb Ischemia Treatment Market by Treatment Type (Angioplasty & Stenting, Endarterectomy, Hyperbaric Oxygen Therapy), End-Use (Home Health Care, Hospitals, Outpatient Surgical Centers) - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 197 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

危急性肢体缺血治疗市场2023年估值为41.1亿美元，预计到2024年将达到44.6亿美元，复合年增长率为8.84%，到2030年将达到74.5亿美元。

危急性肢体缺血(CLI) 是一种严重的动脉阻塞，会显着减少流向肢体的血流量，如果不治疗，有截肢的风险。由于周边动脉疾病和糖尿病等慢性疾病的高盛行率，CLI 治疗对于改善患者预后和生活品质至关重要。其应用范围从外科手术（例如旁路移植术和动脉内膜切除术）到非手术方法（包括血管成形术）和新的基于细胞的治疗方法。最终用途范围涵盖医院、门诊医疗中心和血管专科诊所，反映了有效治疗所需的多学科方法。全球人口老化、糖尿病盛行率上升以及医疗技术进步推动了市场成长。然而，发展中地区治疗费用高、医疗基础设施不足等因素带来了挑战。监管障碍和加强临床试验通讯协定的需求也阻碍了市场的进步。主要的潜在机会在于微创治疗和个人化医疗方法的开发，生物可吸收支架和干细胞疗法等创新显示出前景。生物技术公司和研究机构之间的策略联盟可以促进创新并加强市场准入。重要的是要专注于为服务不足的市场开发经济上可行的解决方案。患者和初级保健提供者对早期 CLI 症状缺乏认识也会导致治疗延误。市场相关人员必须注重教育工作，以传播理解并促进早期诊断。有许多机会利用数位医疗技术（例如远端医疗和人工智慧诊断工具）来提高患者监测和治疗效果。未来，基因组学的进步以及人工智慧与个人化治疗计划的整合将带来显着的成长途径。儘管面临挑战，在持续研究和以患者为中心的推动下，CLI 治疗市场有望取得重大进展。

主要市场统计
基准年[2023] 41.1亿美元
预测年份 [2024] 44.6亿美元
预测年份 [2030] 74.5亿美元
复合年增长率（%） 8.84%

市场动态：快速发展的危急性肢体缺血治疗市场的关键市场洞察

供需的动态交互作用正在改变危急性肢体缺血治疗市场。了解这些不断变化的市场动态可以帮助企业做出明智的投资决策、策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，同时消费行为及其对製造成本的影响以及对采购趋势的影响。

  • 市场驱动因素
    • 糖尿病和肥胖症盛行率不断增加
    • 微创手术与再生医学的创新
    • 提高患者和临床医生对早期诊断和治疗方案的认识
  • 市场限制因素
    • 併发症的风险
  • 市场机会
    • 干细胞疗法和基因疗法的创新
    • 机器人手术和混合手术室的进展
  • 市场挑战
    • 与先进治疗方法相关的高成本

波特五力：驾驭危急性肢体缺血治疗市场的策略工具

波特的五力框架是了解市场竞争格局的重要工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：了解危急性肢体缺血治疗市场的外在影响

外部宏观环境因素在塑造危急性肢体缺血治疗市场的绩效动态方面发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并帮助他们做出积极主动的决策。

市场占有率分析 了解危急性肢体缺血治疗市场的竞争状况

对危急性肢体缺血治疗市场的详细市场占有率分析可以对供应商的绩效进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV 定位矩阵危急性肢体缺血治疗市场供应商的绩效评估

FPNV 定位矩阵是评估危急性肢体缺血治疗市场供应商的关键工具。此矩阵允许业务组织根据商务策略和产品满意度评估供应商，从而做出与其目标相符的明智决策。这四个象限使您能够清晰、准确地划分供应商，并确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析和建议描绘了危急性肢体缺血治疗市场的成功之路

对于旨在加强其在全球市场的影响力的公司来说，对危急性肢体缺血治疗市场的策略分析至关重要。透过审查关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机并取得长期成功。

本报告对市场进行了全面分析，涵盖关键重点领域：

1. 市场渗透率：详细检视当前市场环境、主要企业的广泛资料、评估其在市场中的影响力和整体影响力。

2. 市场开拓：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监理核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点在于有望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 糖尿病和肥胖症增加
      • 微创手术与再生医学的创新
      • 提高患者和医生对早期诊断和治疗方案的认识
    • 抑制因素
      • 手术併发症的风险
    • 机会
      • 干细胞和基因治疗的创新
      • 机器人手术和混合手术室的进展
    • 任务
      • 与先进治疗方法相关的高成本
  • 市场区隔分析
    • 治疗类型：采用血管成形术及置入术作为微创手术
    • 最终用途：医院在 CLI 患者的诊断、治疗和紧急护理中的重要性
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社群
    • 技术的
    • 合法地
    • 环境

第六章依治疗类型分類的危急性肢体缺血治疗市场

  • 血管成形术和置入术
  • 切除术
  • 高压氧气疗法
  • 药物治疗
  • 外科搭桥手术

第七章危急性肢体缺血治疗市场：依最终用途

  • 居家医疗
  • 医院
  • 门诊手术中心
  • 血管专科门诊
  • 创伤护理中心

第八章美洲危急性肢体缺血治疗市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第九章亚太地区危急性肢体缺血治疗市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十章 欧洲、中东、非洲危急性肢体缺血治疗市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十一章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
    • 雅培 Esprit BTK 系统先进治疗严重四肢瘫痪
    • RimFlow 系统为面临截肢风险的严重周边动脉疾病患者带来新希望
  • 战略分析和建议

公司名单

  • Abbott Laboratories
  • Ambulero Inc
  • Amgen Inc.
  • Antidote Therapeutics Inc
  • Athersys Inc
  • Boston Scientific Corporation
  • Caladrius Biosciences Inc
  • Cardiovascular Systems, Inc.
  • Cesca Therapeutics Inc.
  • Constant Therapeutics LLC
  • Cynata Therapeutics Ltd
  • Eli Lilly and Company
  • Gurus BioPharm Inc
  • Helixmith Co Ltd
  • Hemostemix Inc
  • ID Pharma Co Ltd
  • ImmuneCyte Inc
  • Ixaka Ltd
  • LimFlow SA
  • Lisata Therapeutics
  • Medtronic plc
  • Micro Medical Solutions
  • Novartis AG
  • Pluristem Therapeutics Inc.
  • Rexgenero Ltd.
  • Sanofi SA
  • Stempeutics Research Pvt Ltd.
  • Teva Pharmaceutical Industries Ltd.
Product Code: MRR-6B0EA07975A2

The Critical Limb Ischemia Treatment Market was valued at USD 4.11 billion in 2023, expected to reach USD 4.46 billion in 2024, and is projected to grow at a CAGR of 8.84%, to USD 7.45 billion by 2030.

Critical Limb Ischemia (CLI) is a severe obstruction of the arteries which significantly reduces blood flow to the extremities and poses a risk of amputation if untreated. Necessitated by the high prevalence of peripheral arterial disease and associated chronic conditions like diabetes, CLI treatment is vital for enhancing patient outcomes and quality of life. Applications range from surgical interventions, such as bypass grafting and endarterectomy, to non-surgical methods including angioplasty, and emerging cell-based therapies. The end-use scope spans hospitals, ambulatory care centers, and specialized vascular clinics, reflecting the multidisciplinary approach required for effective treatment. Market growth is driven by an aging global population, increasing incidence of diabetes, and advancements in medical technologies. However, factors like high treatment costs and inadequate healthcare infrastructure in developing regions present challenges. Regulatory hurdles and the need for enhanced clinical trial protocols also impede market progress. Key potential opportunities lie in the development of minimally invasive treatments and personalized medicine approaches; innovations like bioresorbable scaffolds and stem cell therapies show promise. Strategic collaborations between biotech firms and research institutions can expedite innovation and enhance market entry. Emphasis on developing economically viable solutions for underserved markets is crucial. Limitations also stem from a lack of awareness among patients and primary care providers about early-stage CLI symptoms, which delays treatment. Market players must focus on educational initiatives to broaden understanding and foster early diagnosis. Opportunities abound in leveraging digital health technologies, including telemedicine and AI-driven diagnostic tools, which enhance patient monitoring and treatment efficacy. Looking forward, advancements in genomics and the integration of AI in personalized treatment plans represent substantial avenues for growth. Despite its challenges, the CLI treatment market is poised for significant advancements fueled by ongoing research and a patient-centric focus.

KEY MARKET STATISTICS
Base Year [2023] USD 4.11 billion
Estimated Year [2024] USD 4.46 billion
Forecast Year [2030] USD 7.45 billion
CAGR (%) 8.84%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Critical Limb Ischemia Treatment Market

The Critical Limb Ischemia Treatment Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Increasing prevalence of diabetes and obesity
    • Innovations in minimally invasive procedures and regenerative medicine
    • Increased patient and clinician awareness about early diagnosis and treatment options
  • Market Restraints
    • Risk of procedural complications
  • Market Opportunities
    • Innovations in stem cell therapy and gene therapy
    • Advances in robotic surgery and hybrid operating rooms
  • Market Challenges
    • High costs associated with advanced treatment modalities

Porter's Five Forces: A Strategic Tool for Navigating the Critical Limb Ischemia Treatment Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Critical Limb Ischemia Treatment Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Critical Limb Ischemia Treatment Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Critical Limb Ischemia Treatment Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Critical Limb Ischemia Treatment Market

A detailed market share analysis in the Critical Limb Ischemia Treatment Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Critical Limb Ischemia Treatment Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Critical Limb Ischemia Treatment Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Critical Limb Ischemia Treatment Market

A strategic analysis of the Critical Limb Ischemia Treatment Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Critical Limb Ischemia Treatment Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Ambulero Inc, Amgen Inc., Antidote Therapeutics Inc, Athersys Inc, Boston Scientific Corporation, Caladrius Biosciences Inc, Cardiovascular Systems, Inc., Cesca Therapeutics Inc., Constant Therapeutics LLC, Cynata Therapeutics Ltd, Eli Lilly and Company, Gurus BioPharm Inc, Helixmith Co Ltd, Hemostemix Inc, ID Pharma Co Ltd, ImmuneCyte Inc, Ixaka Ltd, LimFlow SA, Lisata Therapeutics, Medtronic plc, Micro Medical Solutions, Novartis AG, Pluristem Therapeutics Inc., Rexgenero Ltd., Sanofi S.A., Stempeutics Research Pvt Ltd., and Teva Pharmaceutical Industries Ltd..

Market Segmentation & Coverage

This research report categorizes the Critical Limb Ischemia Treatment Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Treatment Type, market is studied across Angioplasty & Stenting, Endarterectomy, Hyperbaric Oxygen Therapy, Medication, and Surgical Bypass.
  • Based on End-Use, market is studied across Home Health Care, Hospitals, Outpatient Surgical Centers, Specialized Vascular Clinics, and Wound Care Centers.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing prevalence of diabetes and obesity
      • 5.1.1.2. Innovations in minimally invasive procedures and regenerative medicine
      • 5.1.1.3. Increased patient and clinician awareness about early diagnosis and treatment options
    • 5.1.2. Restraints
      • 5.1.2.1. Risk of procedural complications
    • 5.1.3. Opportunities
      • 5.1.3.1. Innovations in stem cell therapy and gene therapy
      • 5.1.3.2. Advances in robotic surgery and hybrid operating rooms
    • 5.1.4. Challenges
      • 5.1.4.1. High costs associated with advanced treatment modalities
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Treatment Type: Adoption of angioplasty and stenting as minimally invasive procedures
    • 5.2.2. End-Use: Importance of hospitals in the diagnosis, treatment, and emergency care of CLI patients
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Critical Limb Ischemia Treatment Market, by Treatment Type

  • 6.1. Introduction
  • 6.2. Angioplasty & Stenting
  • 6.3. Endarterectomy
  • 6.4. Hyperbaric Oxygen Therapy
  • 6.5. Medication
  • 6.6. Surgical Bypass

7. Critical Limb Ischemia Treatment Market, by End-Use

  • 7.1. Introduction
  • 7.2. Home Health Care
  • 7.3. Hospitals
  • 7.4. Outpatient Surgical Centers
  • 7.5. Specialized Vascular Clinics
  • 7.6. Wound Care Centers

8. Americas Critical Limb Ischemia Treatment Market

  • 8.1. Introduction
  • 8.2. Argentina
  • 8.3. Brazil
  • 8.4. Canada
  • 8.5. Mexico
  • 8.6. United States

9. Asia-Pacific Critical Limb Ischemia Treatment Market

  • 9.1. Introduction
  • 9.2. Australia
  • 9.3. China
  • 9.4. India
  • 9.5. Indonesia
  • 9.6. Japan
  • 9.7. Malaysia
  • 9.8. Philippines
  • 9.9. Singapore
  • 9.10. South Korea
  • 9.11. Taiwan
  • 9.12. Thailand
  • 9.13. Vietnam

10. Europe, Middle East & Africa Critical Limb Ischemia Treatment Market

  • 10.1. Introduction
  • 10.2. Denmark
  • 10.3. Egypt
  • 10.4. Finland
  • 10.5. France
  • 10.6. Germany
  • 10.7. Israel
  • 10.8. Italy
  • 10.9. Netherlands
  • 10.10. Nigeria
  • 10.11. Norway
  • 10.12. Poland
  • 10.13. Qatar
  • 10.14. Russia
  • 10.15. Saudi Arabia
  • 10.16. South Africa
  • 10.17. Spain
  • 10.18. Sweden
  • 10.19. Switzerland
  • 10.20. Turkey
  • 10.21. United Arab Emirates
  • 10.22. United Kingdom

11. Competitive Landscape

  • 11.1. Market Share Analysis, 2023
  • 11.2. FPNV Positioning Matrix, 2023
  • 11.3. Competitive Scenario Analysis
    • 11.3.1. Advanced Treatment for Critical Limb-Threatening Ischemia with Abbott's Esprit BTK System
    • 11.3.2. LimFlow System Offers New Hope for Severe Peripheral Artery Disease Patients Facing Amputation
  • 11.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Abbott Laboratories
  • 2. Ambulero Inc
  • 3. Amgen Inc.
  • 4. Antidote Therapeutics Inc
  • 5. Athersys Inc
  • 6. Boston Scientific Corporation
  • 7. Caladrius Biosciences Inc
  • 8. Cardiovascular Systems, Inc.
  • 9. Cesca Therapeutics Inc.
  • 10. Constant Therapeutics LLC
  • 11. Cynata Therapeutics Ltd
  • 12. Eli Lilly and Company
  • 13. Gurus BioPharm Inc
  • 14. Helixmith Co Ltd
  • 15. Hemostemix Inc
  • 16. ID Pharma Co Ltd
  • 17. ImmuneCyte Inc
  • 18. Ixaka Ltd
  • 19. LimFlow SA
  • 20. Lisata Therapeutics
  • 21. Medtronic plc
  • 22. Micro Medical Solutions
  • 23. Novartis AG
  • 24. Pluristem Therapeutics Inc.
  • 25. Rexgenero Ltd.
  • 26. Sanofi S.A.
  • 27. Stempeutics Research Pvt Ltd.
  • 28. Teva Pharmaceutical Industries Ltd.

LIST OF FIGURES

  • FIGURE 1. CRITICAL LIMB ISCHEMIA TREATMENT MARKET RESEARCH PROCESS
  • FIGURE 2. CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY END-USE, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY END-USE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. AMERICAS CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 11. AMERICAS CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. UNITED STATES CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 13. UNITED STATES CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. ASIA-PACIFIC CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. ASIA-PACIFIC CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. EUROPE, MIDDLE EAST & AFRICA CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. CRITICAL LIMB ISCHEMIA TREATMENT MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 19. CRITICAL LIMB ISCHEMIA TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. CRITICAL LIMB ISCHEMIA TREATMENT MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. CRITICAL LIMB ISCHEMIA TREATMENT MARKET DYNAMICS
  • TABLE 7. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY ANGIOPLASTY & STENTING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY ENDARTERECTOMY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY HYPERBARIC OXYGEN THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY MEDICATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY SURGICAL BYPASS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY HOME HEALTH CARE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY OUTPATIENT SURGICAL CENTERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY SPECIALIZED VASCULAR CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY WOUND CARE CENTERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. AMERICAS CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 20. AMERICAS CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 21. AMERICAS CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 22. ARGENTINA CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 23. ARGENTINA CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 24. BRAZIL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 25. BRAZIL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 26. CANADA CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 27. CANADA CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 28. MEXICO CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 29. MEXICO CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 30. UNITED STATES CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 31. UNITED STATES CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 32. UNITED STATES CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 33. ASIA-PACIFIC CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 34. ASIA-PACIFIC CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 35. ASIA-PACIFIC CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 36. AUSTRALIA CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 37. AUSTRALIA CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 38. CHINA CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 39. CHINA CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 40. INDIA CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 41. INDIA CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 42. INDONESIA CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 43. INDONESIA CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 44. JAPAN CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 45. JAPAN CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 46. MALAYSIA CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 47. MALAYSIA CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 48. PHILIPPINES CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 49. PHILIPPINES CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 50. SINGAPORE CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 51. SINGAPORE CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 52. SOUTH KOREA CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 53. SOUTH KOREA CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 54. TAIWAN CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 55. TAIWAN CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 56. THAILAND CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 57. THAILAND CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 58. VIETNAM CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 59. VIETNAM CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 60. EUROPE, MIDDLE EAST & AFRICA CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 61. EUROPE, MIDDLE EAST & AFRICA CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 62. EUROPE, MIDDLE EAST & AFRICA CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 63. DENMARK CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 64. DENMARK CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 65. EGYPT CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 66. EGYPT CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 67. FINLAND CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 68. FINLAND CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 69. FRANCE CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 70. FRANCE CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 71. GERMANY CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 72. GERMANY CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 73. ISRAEL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 74. ISRAEL CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 75. ITALY CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 76. ITALY CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 77. NETHERLANDS CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 78. NETHERLANDS CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 79. NIGERIA CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 80. NIGERIA CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 81. NORWAY CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 82. NORWAY CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 83. POLAND CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 84. POLAND CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 85. QATAR CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 86. QATAR CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 87. RUSSIA CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 88. RUSSIA CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 89. SAUDI ARABIA CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 90. SAUDI ARABIA CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 91. SOUTH AFRICA CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 92. SOUTH AFRICA CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 93. SPAIN CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 94. SPAIN CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 95. SWEDEN CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 96. SWEDEN CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 97. SWITZERLAND CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 98. SWITZERLAND CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 99. TURKEY CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 100. TURKEY CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 101. UNITED ARAB EMIRATES CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 102. UNITED ARAB EMIRATES CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 103. UNITED KINGDOM CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 104. UNITED KINGDOM CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 105. CRITICAL LIMB ISCHEMIA TREATMENT MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 106. CRITICAL LIMB ISCHEMIA TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023